Susan Erickson‐Viitanen

Author

Also Known As

S Erickson-Viitanen, S. ERICKSON-VIITANEN, S. ERICKSON‐VIITANEN, S. Erickson-Viitanen, S. Erickson‐Viitanen, S. K. Erickson-Viitanen, SUSAN ERICKSON-VIITANEN, Susan Erickson-Viitanen, Susan Erickson‐Viitanen, Susan K Erickson-Viitanen

103

Publications

8.7K

Citations

H-Index

Concepts

All Affiliations

Wilmington University DuPont (United States)Experimental Station Incyte (United States)The University of Texas MD Anderson Cancer Center

About

Susan Erickson‐Viitanen is an author at Wilmington University specializing in medicine, hiv, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	31	42	3.4K
2	Biochemistry	22	25	2.5K
3	Natural Sciences	21	23	2.4K
4	Health Sciences	6	6	480
5	Public Health	1	1	93

Susan Erickson‐Viitanen

Publications

8.7K

Citations

H-Index

Page 1

	Year	Citations
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, New England Journal of Medicine	2012	2K
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa, New England Journal of Medicine	2010	1.2K
Rational Design of Potent, Bioavailable, Nonpeptide Cyclic Ureas as HIV Protease Inhibitors Patrick Y. S. Lam, Prabhakar K. Jadhav, Charles J. Eyermann, Science Combinatorial ChemistryBioorganic ChemistryNonpeptide Cyclic UreasChemistryHuman Immunodeficiency Virus	1994	834
Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors Jeffrey W. Corbett, Soo S. Ko, James D. Rodgers, Journal of Medicinal Chemistry	2000	299
p-Benzoyl-L-phenylalanine, a new photoreactive amino acid. Photolabeling of calmodulin with a synthetic calmodulin-binding peptide. James C. Kauer, Susan Erickson‐Viitanen, Henry R. Wolfe, Journal of Biological Chemistry 17-Residue Calmodulin-binding PeptidePeptide EngineeringPeptide ScienceChemical BiologyOptogenetics	1986	228
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial Ruben A. Mesa, Jason Gotlib, Vikas Gupta, Journal of Clinical Oncology	2013	189
Cleavage of HIV-1 <i>gag</i> Polyprotein Synthesized In Vitro: Sequential Cleavage by the Viral Protease Susan Erickson‐Viitanen, John P. Manfredi, Paul V. Viitanen, AIDS Research and Human Retroviruses	1989	180
Cyclic HIV Protease Inhibitors: Synthesis, Conformational Analysis, P2/P2‘ Structure−Activity Relationship, and Molecular Recognition of Cyclic Ureas Patrick Y. S. Lam, Yu Ru, Prabhakar K. Jadhav, Journal of Medicinal Chemistry	1996	170
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I Srđan Verstovšek, Ruben A. Mesa, Jason Gotlib, Haematologica Hematological MalignancyOncologyMalignant Blood DisorderMedian 2-Year Follow-upHematology	2013	161
Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450 C. Nicholas Hodge, Paul E. Aldrich, Lee T. Bacheler, Chemistry & Biology Hiv-1 ProteaseBiochemistryMedicineAntiviral Drug DevelopmentDmp 450	1996	148

Page 1